Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2020

01-09-2020 | Multiple Myeloma | Letter to the Editor

Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

Authors: Vincenzo Apolito, Luisa Giaccone, Simone Ferrero, Alessandra Larocca, Federica Cavallo, Marta Coscia, Eloise Beggiato, Sara Butera, Federica Martella, Cristina Dainese, Giusy Cetani, Matilde Scaldaferri, Francesco Cattel, Mario Boccadoro, Dario Ferrero, Benedetto Bruno, Marco Cerrano

Published in: Annals of Hematology | Issue 9/2020

Login to get access

Excerpt

Dear Editor, …
Appendix
Available only for authorised users
Literature
1.
Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P (2018) From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 103:197–211. https://​doi.​org/​10.​3324/​haematol.​2017.​174573CrossRefPubMedPubMedCentral
2.
3.
Schmitt T, Goldschmidt H, Neben K, Freiberger A, Hüsing J, Gronkowski M, Thalheimer M, Pelzl LH, Mikus G, Burhenne J, Ho AD, Egerer G (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420. https://​doi.​org/​10.​1200/​JCO.​2013.​55.​0095CrossRefPubMed
4.
Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T, Miyazawa Y, Matsumoto M, Sawamura M, Manaka A (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105:478–484. https://​doi.​org/​10.​1007/​s12185-016-2152-6CrossRefPubMed
5.
6.
Pastore D, Bruno B, Carluccio P, de Candia MS, Mammoliti S, Borghero C, Chierichini A, Pavan F, Casini M, Pini M, Nassi L, Greco R, Tambaro FP, Stefanoni P, Console G, Marchesi F, Facchini L, Mussetti A, Cimminiello M, Saglio F, Vincenti D, Falcioni S, Chiusolo P, Olivieri J, Natale A, Faraci M, Cesaro S, Marotta S, Proia A, Donnini I, Caravelli D, Zuffa E, Iori AP, Soncini E, Bozzoli V, Pisapia G, Scalone R, Villani O, Prete A, Ferrari A, Menconi M, Mancini G, Gigli F, Gargiulo G, Bruno B, Patriarca F, Bonifazi F (2020) Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Ann Hematol 99:867–875. https://​doi.​org/​10.​1007/​s00277-020-03945-3CrossRefPubMed
7.
Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M (2018) A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 29:452–458. https://​doi.​org/​10.​1093/​annonc/​mdx698CrossRefPubMed
8.
Botteman M, Nickel K, Corman S, Turini M, Binder G (2020) Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer 28:857–866. https://​doi.​org/​10.​1007/​s00520-019-04824-yCrossRefPubMed
9.
10.
Trifilio S, Welles C, Seeger K, Mehta S, Fishman MA, McGowan K, Strejcek K, Eiten E, Pirotte C, Lucier E, DeFrates S, Mehta J (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 17:584–589. https://​doi.​org/​10.​1016/​j.​clml.​2017.​06.​012CrossRefPubMed
Metadata
Title
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
Authors
Vincenzo Apolito
Luisa Giaccone
Simone Ferrero
Alessandra Larocca
Federica Cavallo
Marta Coscia
Eloise Beggiato
Sara Butera
Federica Martella
Cristina Dainese
Giusy Cetani
Matilde Scaldaferri
Francesco Cattel
Mario Boccadoro
Dario Ferrero
Benedetto Bruno
Marco Cerrano
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04180-6

Other articles of this Issue 9/2020

Annals of Hematology 9/2020 Go to the issue

Original Article

Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany

Letter to the Editor

Rare primary extramedullary hematopoiesis of the thyroid without intranodular vascularity and mutations in the JAK2, MPL, and calreticulin genes

Letter to the Editor

Nationwide prevalence and trends in acute cardiovascular events and in-hospital mortality among adult African Americans with sickle cell trait

Letter to the Editor

Dutcher bodies in IgA multiple myeloma

Letter to the Editor

Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia

Review Article

Thalassemia in the emergency department: special considerations for a rare disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits